HYPERA S.A. SPONS.ADR 1 Logo
US44914U1060
A2JETE
HYPMY

HYPERA S.A. SPONS.ADR 1

Forecast

Buy
  0
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, HYPERA S.A. SPONS.ADR 1 has already paid €0.0921 in dividends. The last payout was in October.

Financials

In the last quarter, HYPERA S.A. SPONS.ADR 1 had revenue of €421.92M and net profit of €90.62M

(EUR) September 2026
YoY
Revenue 421.92M 18.29%
Gross profit 250.89M 19.36%
Net profit 90.62M 23.65%
EBITDA 136.68M 5.35%

Fundamentals

Metric Value
Market capitalization
€2.35B
Number of shares
696.72M
52-week high/low
€5.26 - €3.09
Dividend yield
2.62%
Dividends TTM
€0.0921
Beta
0.11
P/E ratio
8.06
PEG ratio
0.08
P/B ratio
1.04
P/S ratio
1.70

Company profile

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

Name
HYPERA S.A. SPONS.ADR 1
CEO
Breno Toledo Pires de Oliveira
Headquarters São Paulo, sp
Brazil
Website
IPO
10/15/2010
Employees 10,564

Ticker symbols

Exchange Symbol
Pnk
HYPMY
Frankfurt
HM6A.F
🍪

Parqet  uses cookies. Learn more